Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Slick turnaround against Syk

When Rigel Pharmaceuticals Inc. put out its first Phase II data on tamatinib, the compound met the primary endpoint in refractory immune thrombocytopenic purpura. But investors balked, likely because of a high rate of adverse events in responders. Last week, investors came flooding back when the company released new data in rheumatoid arthritis, this time showing that the oral small molecule may match the efficacy of marketed injectable biologics

Read the full 698 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers